The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.a

Myocarditis (can be fulminant)

Publications

Cesa K, Cunningham C, Harris T, Sunseri W

A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease.

Cureus. 2022;14(6):e26366

Comité Nacional de Neumonología, Sociedad Argentina de Pediatría

[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].

Archivos argentinos de pediatria. 2019;117(2):S120-S134

Lezcano-Gort LE, Gómez-Barrado JJ, Mogollón-Jiménez MV, Garcipérez-de-Vargas-Díaz FJ

Hypersensitivity perimyocarditis after the first dose of infliximab.

Revista espanola de enfermedades digestivas. 2015;107(4):249

Slattery E, Ismail N, Sheridan J, Eustace K, Harewood G, Patchett S

Myocarditis associated with infliximab: a case report and review of the literature.

Inflammatory bowel diseases. 2011;17(7):1633-4